New allergy shots show promise for dust mite sufferers
NCT ID NCT07427576
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a type of allergy immunotherapy (Clustoid® Max Forte) in 140 people aged 5 to 65 with dust mite allergies. The goal was to see if it reduces allergy and asthma symptoms and the need for medication over one year. Results were measured by symptom scores and medication use, and safety was monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clínica Doctor García Robaina
Santa Cruz de Tenerife, Canary Islands, 38002, Spain
-
Nuestra Señora de Candelaria
Santa Cruz de Tenerife, Canary Islands, 38010, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?